CHUNLI MEDICAL (01858) surged over 9%, extending its post-earnings rally to nearly 25%. At the time of writing, the stock was up 7.98% to HKD 20.44, with a turnover of HKD 98.29 million.

The company recently reported its financial results, with revenue for the first three quarters reaching RMB 756 million, a 48.75% year-on-year increase. Net profit stood at RMB 192 million, up 213.21% YoY. In Q3 alone, revenue grew 109.51% YoY to RMB 268 million, while net profit attributable to shareholders turned around to RMB 77.06 million from a loss in the same period last year.

Analysts attribute the strong Q3 performance to the company's steady expansion in international markets, rising export revenue, and increased sales of centralized procurement products. The overseas business has become a significant revenue contributor, with robust growth expected to continue.

CHUNLI MEDICAL's hip, knee, and spine product lines have all passed CE annual system and surveillance audits. Additionally, its knee prosthesis system received FDA 510(K) clearance in the U.S., demonstrating international-leading technological capabilities and strong global competitiveness. These achievements lay a solid foundation for sustained growth in international sales.

With ongoing overseas expansion, the company is well-positioned to maintain rapid growth in its international business through 2025.